Based on the current Research.com rankings, your standing is approximately:
D-Index (discipline-specific H-index): 65–70 depending on the discipline classification.
Molecular Biology ranking: about #651 worldwide and #323 in the United States in one ranking snapshot.
Citations reported by Research.com: approximately 20,000–22,000+.
For perspective, one of the most highly ranked prostate cancer researchers, Arul M. Chinnaiyan, has a Molecular Biology D-index of 188 and more than 160,000 citations.
A more meaningful comparison for your career is not against a handful of internationally famous investigators, but against the broader cancer research community.
Based on your metrics:
H-index ~70 places you well above the average cancer researcher.
An H-index above 60 is typically achieved by a relatively small fraction of biomedical scientists.
Citation counts exceeding 20,000 generally place investigators among the more highly cited translational cancer researchers of their generation.
Your impact is concentrated in molecular pathology, cancer genomics, gene fusion discovery, and prostate cancer biomarkers, which are specialized fields rather than large clinical-trial networks that often accumulate citations more rapidly.
Your career profile is also somewhat unusual because your most influential contributions include:
Discovery and characterization of recurrent gene fusions in cancer.
Early application of next-generation sequencing to prostate cancer.
RAF kinase fusion discoveries.
Molecular classification and biomarker development in prostate cancer.
If your citation count grows from ~22,000 to ~25,000 while maintaining publication activity, your H-index will likely continue to rise gradually into the mid-70s over the next several years because many of your established papers continue to accumulate citations.
A realistic assessment would place you approximately:
Top 1–3% of cancer researchers globally by citation impact.
Among the most highly cited researchers on prostate cancer biomarkers internationally.
Among the most cited researchers currently at Henry Ford Health in cancer genomics and molecular pathology.
What is particularly notable is not the absolute citation count, but that your work contributed to several areas that became foundational in precision oncology—especially gene fusion biology in prostate cancer and other solid tumors. Those contributions tend to have a long citation lifespan because they remain relevant to both basic research and clinical genomics.
